Injectable Small Intestine Submucosal Extracellular Matrix in an Acute Myocardial Infarction Model

Toeg, Hadi; Tiwari-Pandey, Rashmi; Seymour, Richard J.; Ahmadi, Ali; Crowe, Suzanne; Vulesevic, Branka; Suuronen, Erik J.; Ruel, Marc

doi:10.1016/j.athoracsur.2013.06.063

Cited by 40 publications

(46 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In terms of applicability in the heart, the SIS-ECM decellularized matrix has been demonstrated to be feasible and safe in 40 patients with congenital heart disease [174], while its utility for the repair of ischemic myocardium has been shown in murine [175, 176] and rabbit [177] models of myocardial infarction with moderate improvements in cardiac function. Similar to the SIS-ECM, decellularized matrix from rat [178] or porcine [179, 180] hearts has been used for myocardial repair in rat [178, 179] as well as porcine [180] models of myocardial infarction, the latter being delivered via a percutaneous transendocardial injection, demonstrating potential translatability to human therapies.…”

Section: Therapies For Striated Muscle Disordersmentioning

confidence: 99%

Striated muscle function, regeneration, and repair

Shadrin

Khodabukus

2016

Cell. Mol. Life Sci.

View full text Add to dashboard Cite

As the only striated muscle tissues in the body, skeletal and cardiac muscle share numerous structural and functional characteristics, while exhibiting vastly different size and regenerative potential. Healthy skeletal muscle harbors a robust regenerative response that becomes inadequate after large muscle loss or in degenerative pathologies and aging. In contrast, the mammalian heart loses its regenerative capacity shortly after birth, leaving it susceptible to permanent damage by acute injury or chronic disease. In this review, we compare and contrast the physiology and regenerative potential of native skeletal and cardiac muscles, mechanisms underlying striated muscle dysfunction, and bioengineering strategies to treat muscle disorders. We focus on different sources for cellular therapy, biomaterials to augment the endogenous regenerative response, and progress in engineering and application of mature striated muscle tissues in vitro and in vivo. Finally, we discuss the challenges and perspectives in translating muscle bioengineering strategies to clinical practice.

show abstract

Section: Therapies For Striated Muscle Disordersmentioning

confidence: 99%

Striated muscle function, regeneration, and repair

Shadrin

Khodabukus

2016

Cell. Mol. Life Sci.

View full text Add to dashboard Cite

show abstract

“…7-14 days post-MI), as dictated by medical guidelines (46). Efficacy should also be assessed at different anatomical sites when relevant, as was done for the in vivo evaluation of pig SIS, which was tested in the left ventricle after occlusion of the left anterior descending coronary artery to simulate post-MI treatment and in the right outflow tract to evaluate use for transmural vascular grafting (47,48). To expedite progress and increase confidence in the products tested, both negative and positive results from all preclinical and early clinical studies should be published.…”

Section: Translational Process and Clinical Trialsmentioning

confidence: 99%

Building New Hearts: A Review of Trends in Cardiac Tissue Engineering

Taylor¹,

Sampaio²,

Gobin³

2014

American Journal of Transplantation

View full text Add to dashboard Cite

“…In our studies, scans were performed during weeks 3 and 4 after surgery to target the window that might typically be used to investigate the efficacy of new therapies [7,25,[29][30][31]. Even if the MI regional iMBF values were equivalent between test and retest studies, cardiac remodelling progresses continuously up to 6 months after permanent LAD artery ligation [32].…”

Section: Regional Mbfmentioning

confidence: 99%